U.S. PHARMACOPEIA

Search USP29  
Methsuximide
Click to View Image
C12H13NO2 203.24

2,5-Pyrrolidinedione, 1,3-dimethyl-3-phenyl-, (±)-.
(±)-N,2-Dimethyl-2-phenylsuccinimide [77-41-8].
» Methsuximide contains not less than 97.0 percent and not more than 103.0 percent of C12H13NO2, calculated on the dried basis.
Packaging and storage— Preserve in tight containers.
Identification—
B: Ultraviolet Absorption 197U
Solution: 350 µg per mL.
Medium: alcohol.
Melting range 741: between 50 and 56, determined by a Class I procedure, except that the test specimen is inserted into the bath at about room temperature.
Loss on drying 731 Dry it over phosphorus pentoxide for 16 hours: it loses not more than 0.5% of its weight.
Residue on ignition 281: not more than 0.2%.
Limit of cyanide— Dissolve 1.0 g in 10 mL of alcohol, and add 3 drops of ferrous sulfate TS, 1 mL of 1 N sodium hydroxide, and a few drops of ferric chloride TS. Warm gently, and finally acidify with 2 N sulfuric acid: no blue precipitate or blue color develops within 15 minutes.
Chromatographic purity—
Mobile phase and Chromatographic system—Proceed as directed in the Assay. To evaluate the system suitability requirements, use the Standard preparation as prepared in the Assay.
Standard solution— Dissolve an accurately weighed quantity of USP Methsuximide RS in Mobile phase, and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of about 6.0 µg per mL.
Test solution— Transfer about 300 mg of Methsuximide, accurately weighed, to a 50-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure all of the peak responses. Calculate the percentage of each impurity in the portion of Methsuximide taken by the formula:
0.1(CS / CU)(ri / rS),
in which CS is the concentration, in µg per mL, of USP Methsuximide RS in the Standard solution; CU is the concentration, in mg per mL, of Methsuximide in the Test solution; ri is the peak response for each impurity obtained from the Test solution; and rS is the peak response for methsuximide obtained from the Standard solution: not more than 0.1% of any individual impurity is found; and not more than 2.0% of total impurities is found.
Organic volatile impurities, Method V 467: meets the requirements.
Solvent— Use dimethyl sulfoxide.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay—
Mobile phase— Prepare a filtered and degassed mixture of water and acetonitrile (11:9). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Dissolve an accurately weighed quantity of USP Methsuximide RS in Mobile phase, and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of about 0.6 mg per mL.
Assay preparation— Transfer about 120 mg of Methsuximide, accurately weighed, to a 200-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix.
Chromatographic system— The liquid chromatograph is equipped with a 254-nm detector and a 3.9-mm × 30-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the column efficiency is not less than 5800 theoretical plates; the tailing factor is not more than 1.3; and the relative standard deviation for replicate injections is not more than 0.6%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C12H13NO2 in the portion of Methsuximide taken by the formula:
200CS(rU / rS),
in which CS is the concentration, in mg per mL, of USP Methsuximide RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Ravi Ravichandran, Ph.D., Senior Scientist
Expert Committee : (MDPP05) Monograph Development-Psychiatrics and Psychoactives
USP29–NF24 Page 1390
Phone Number : 1-301-816-8330